KFDA approves subcutaneous formulation of Orencia for rheumatoid arthritis

Published: 2013-06-14 06:57:00

Updated: 2013-06-14 06:57:00

The Ministry of Food and Drug Safety (MFDS) has approved a subcutaneous formulation of Orencia (abatacept; BMS Korea) for the reduction of signs and symptoms in adults with moderate to severe rheumatoid arthritis.

The once-weekly, self-injectable subcutaneous formulation of Orencia is a fixed...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK